EU approves Lynparza for platinum-sensitive relapsed ovarian cancer

EU approves Lynparza for platinum-sensitive relapsed ovarian cancer
Credit: Shutterstock.com/ Dmitry Kalinovsky

AstraZeneca and Merck have gained approval from the European Medicines Agency (EMA) for Lynparza tablets as a maintenance therapy for the treatment of platinum-sensitive relapsed ovarian cancer.

“With this new approval for Lynparza, we will now be able to offer more women with platinum-sensitive ovarian cancer, regardless of their BRCA status, a chance to achieve long-term disease control with an oral medicine that has a well-characterised safety and tolerability profile,” said Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit at AstraZeneca.

Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, added: “This is an important development for the thousands of women in Europe living with advanced ovarian cancer, historically a difficult-to-treat disease.”

The approval was based on two randomised trials, SOLO-2 and Study 19, which showed that Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed ovarian cancer patients compared to placebo.